Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 8/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | YES1 | P07947 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336353 | 0.85 | ACHE (0.47) | PIK3CGPIK3CAPIK3CDDYRK1ADYRK1B | |
| SCHEMBL3925325 | 0.85 | ADORA3 (0.48) | GAKPIK3CGPIK3CAPIK3CDADORA3 | |
| SCHEMBL4455771 | 0.82 | ADORA3 (0.47) | PIK3CGPIK3CAPIK3CDDYRK1ADYRK1B | |
| SCHEMBL4108181 | 0.79 | ADORA3 (0.41) | PIK3CGPIK3CAPIK3CDADORA3MAPK1 | |
| SCHEMBL3924817 | 0.77 | KMO (0.42) | PIK3CGPIK3CAPIK3CDADORA3MAPK1 | |
| SCHEMBL4062926 | 0.76 | AAK1 (0.46) | AURKBDYRK1ADYRK1BYES1MAPK1 | |
| SCHEMBL4526335 | 0.74 | GAK (0.48) | GAKPIK3CGPIK3CAAURKBDYRK1A | |
| SCHEMBL4452166 | 0.73 | LIG1 (0.44) | PIK3CGPIK3CAPIK3CDDYRK1ADYRK1B | |
| SCHEMBL3337363 | 0.71 | ADORA3 (0.40) | PIK3CGPIK3CAPIK3CDADORA3MAPK1 | |
| SCHEMBL4448818 | 0.71 | ALDH1A1 (0.47) | PIK3CGPIK3CAPIK3CDDYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | GAK 1134/4885PIK3CG 547/4885PIK3CA 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.